3,3-Dimethylcyclopentanamine hydrochloride | 212382-62-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3,3-Dimethylcyclopentanamine hydrochloride
• 英文别名: 3,3-Dimethylcyclopentan-1-amine hydrochloride；3,3-dimethylcyclopentan-1-amine;hydrochloride
• CAS: 212382-62-2
• 化学式: C₇H₁₅N*ClH
• mdl: MFCD23144185
• 分子量: 149.664
• InChiKey: HUWKTDJSIIOXTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.32
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3,3-Dimethylcyclopentanamine hydrochloride 、 N-叔丁氧羰基-L-反-2-氮杂二环[3.1.0]己烷-3-羧酸 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (1R,3S,5R)-((3R)-3,3-dimethylcyclopentylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester 、 (1R,3S,5R)-((3S)-3,3-dimethylcyclopentylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
  [FR] MODULATEURS DE LA VOIE DU COMPLÉMENT ET UTILISATIONS DE CEUX-CI

  摘要：

  公开号：

  WO2014002058A3

文献信息

• Benzoic acid derivatives and related compounds as antiarrhythmic agents
  申请人：——

  公开号：US20020137968A1

  公开（公告）日：2002-09-26

  Benzoic acid derivatives of the formula I 1 where X is oxygen, sulfur, —NH, —NR 1 , —N—CN, —N—OR 1 or —N—NO 2 ; Y is a single bond, —C═C—, or —NH; R 1 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclo, or (heterocyclo)alkyl; and R 2 is aryl or heterocyclo. The compounds of formula I are useful in the treatment of arrhythmia.

  公式I的苯甲酸衍生物 其中X为氧、硫、—NH、—NR 1 、—N—CN、—N—OR 1 或—N—NO 2 ； Y为单键、—C═C—或—NH； R 1 为烷基、烯基、炔基、芳基、环烷基、杂环烷基或(杂环烷基)；和 R 2 为芳基或杂环烷基。公式I的化合物在心律失常的治疗中很有用。
• Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
  申请人：Nurix Therapeutics, Inc.

  公开号：US11530229B2

  公开（公告）日：2022-12-20

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

  本发明公开了用于抑制泛素蛋白酶体途径中的 E3 酶 Cbl-b 的化合物、组合物和方法。这些化合物、组合物和方法可用于调节免疫系统，治疗免疫系统可调节的疾病，以及体内、体外或体外细胞的治疗。还公开了包含 Cbl-b 抑制剂和癌症疫苗的药物组合物，以及使用 Cbl-b 抑制剂和癌症疫苗治疗癌症的方法；以及包含 Cbl-b 抑制剂和溶瘤病毒的药物组合物，以及使用 Cbl-b 抑制剂和溶瘤病毒治疗癌症的方法。
• CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF
  申请人：Nurix Therapeutics, Inc.

  公开号：US20210053986A1

  公开（公告）日：2021-02-25

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
• US6624309B1
  申请人：——

  公开号：US6624309B1

  公开（公告）日：2003-09-23
• [EN] CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF<br/>[FR] COMPOSÉS CYANO-CYCLOBUTYLE POUR L'INHIBITION DE CBL-B ET LEURS UTILISATIONS
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2020236654A1

  公开（公告）日：2020-11-26

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.